Innate Pharma IPHA
NASDAQ IPHA
$1.57 -0.01 (-0.51%)
At close: Oct 21, 2026 · 4:00 PM EDT

Innate Pharma (IPHA) Capital Expenditures (2019)

Updated

Innate Pharma's Capital Expenditures came in at -$162,966 for the quarter ended Dec 31, 2025, compared with -$417,821 a year earlier.

Analysis

Innate Pharma (IPHA) Capital Expenditures (2019) Analysis & Trends

For the year ended Dec 31, 2025, Innate Pharma's Capital Expenditures was -$158,174.

  • Going back by year, Capital Expenditures was -$423,194 in the year ended Dec 31, 2024, -$379,683 in the year ended Dec 31, 2023, -$563,866 in the year ended Dec 31, 2022 and -$1.06 million in the year ended Dec 31, 2021.
  • The figure for the quarter ended Dec 31, 2025 represents the highest quarterly Capital Expenditures in data going back to the quarter ended Jun 30, 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 2.93 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 1.32 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 322.00 Mn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 893.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 321.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 1.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 513.00 Mn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 140.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 533.00 Mn
10 Innate Pharma 143.35 Mn -63.85 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2019 -829,245.65
API Access

Innate Pharma Capital Expenditures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=capital-expenditures&ticker=IPHA&period=max&api_key=YOUR_API_KEY